SCHEMBL6079306

SCHEMBL6079306

Oc1cccc(COc2cnccn2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
SLC2A4 P14672 1/20 0.44
ENPP2 Q13822 1/20 0.42
RXFP1 Q9HBX9 2/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
ACHE P22303 1/20 0.39
DHFR P00374 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6082563 0.83 CYP4F2 (0.46) CYP4F2CYP4A11SLC2A4DRD2DRD1
SCHEMBL6079584 0.83 MAOB (0.45) RXFP1ACHENPC1ALDH1A1CYP2D6
SCHEMBL2492332 0.81 KMT2A (0.47) DRD2ALDH1A1CYP2C19CYP1A2PKM
SCHEMBL6227683 0.79 SIRT2 (0.42) RXFP1NPC1ALDH1A1CYP2D6CYP2C19
SCHEMBL6205854 0.78 MEN1 (0.47) RXFP1SMN1; SMN2MRGPRX4MAPK1
SCHEMBL11352994 0.75 GAA (0.49) SMN1; SMN2ALDH1A1CYP3A4
SCHEMBL7081299 0.71 KDM4E (0.36) NPC1ALDH1A1CYP2D6CYP2C19MAPK1
SCHEMBL22964344 0.71 MAPK1 (0.58) MAPK1
SCHEMBL6357776 0.70 MRGPRX4 (0.53) ENPP2DRD2DRD1TAAR1SMN1; SMN2
SCHEMBL10958328 0.69 TBXAS1 (0.49) SLC2A4ENPP2DHFRCYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2006-03-23 US disclosed
EP-1545523-A1 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS Astex Technology Limited (GB) 2005-06-29 EP disclosed
WO-2005002673-A1 RAF KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed
WO-2004004720-A1 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors MAPK1, MAPK3, MAPK10 CYP4F2 1907/4885CYP4A11 701/4885SLC2A4 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.